McKesson Beats Earnings Estimates and Raises Its Full-Year Outlook

Direct answer

McKesson beat Wall Street estimates and raised its full-year profit outlook, according to results reported on November 4, 2026. Revenue reached $111.0 billion in its fiscal second quarter, up 8 percent from a year earlier, and adjusted earnings per share rose 18 percent to $11.68.

What happened

McKesson, one of the largest healthcare distributors in the United States, reported results for its fiscal second quarter of 2027, the quarter ended September 30, 2026. Revenue of $111.0 billion beat the consensus estimate of about $109.90 billion, and adjusted earnings of $11.68 a share beat the consensus estimate of about $10.70 a share, according to Zacks.

On a GAAP basis, net income attributable to McKesson rose 10 percent to $1.22 billion, and diluted earnings per share rose to $10.44 from $8.92 a year earlier. Adjusted earnings strip out one-off items to show the underlying run rate of the business, which is why investors watch that figure closely.

Growth came from all four of the company’s segments. North American Pharmaceutical, its largest business, reported revenue of $91.36 billion, up 6 percent. Oncology and Multispecialty revenue surged 24 percent to $14.98 billion, helped by specialty distribution and provider solutions. Sales of GLP-1 weight loss and diabetes medicines, which McKesson distributes to pharmacies, reached $16 billion, up 26 percent from a year earlier.

McKesson also raised its guidance for the full fiscal year. It now expects adjusted earnings of $45.60 to $46.40 a share, up from $44.20 to $45.00, which implies growth of 17 to 19 percent. It raised its revenue growth forecast to 6 to 10 percent, from 5 to 9 percent, and its adjusted operating profit growth forecast to 12 to 16 percent, from 9 to 13 percent. Operating cash flow for the quarter was $3.07 billion, and free cash flow was $2.95 billion.

Why it matters for beginners

McKesson is a distributor, not a drugmaker. It buys medicines and medical supplies in bulk and delivers them to pharmacies, hospitals, and clinics. When its revenue grows, it usually means more prescriptions and treatments are flowing through the healthcare system, not that McKesson invented a new drug.

A guidance raise matters because it is management’s own forecast. A company raises guidance when it expects the rest of the year to go better than it previously thought. Here, the raise followed a quarter in which both revenue and profit beat estimates, so the higher forecast rests on actual results rather than hope alone.

For beginners, this is also a useful contrast with the technology sell-off happening the same week. Healthcare distributors are steady, everyday businesses, and a strong report from one can stand out while chip and data center stocks fall. Amgen, a drugmaker, also raised its outlook this week, as covered in our post on Amgen raising its 2026 outlook as sales rose 8 percent. That shows the healthcare sector had a stronger week than the broader market.

What to watch next

First, whether GLP-1 medicine sales keep growing at this pace, since they are now a large part of McKesson’s distribution business. Second, whether the oncology and specialty businesses keep growing at double digit rates, because that segment is driving much of the profit growth. Third, whether McKesson delivers on the raised full-year forecast, since guidance only matters if the company hits it. And fourth, the next quarterly report, which will show whether the strong first half of the fiscal year carried through to the second half.

FAQ

What does McKesson do?

McKesson distributes medicines, medical supplies, and healthcare technology to pharmacies, hospitals, clinics, and other care providers. It also runs oncology, multispecialty, and prescription technology businesses.

What is the difference between GAAP earnings and adjusted earnings?

GAAP earnings follow standard accounting rules and include one-off items. Adjusted earnings remove those items to show the underlying performance of the business. McKesson reported GAAP earnings of $10.44 a share and adjusted earnings of $11.68 a share.

Why did McKesson raise its full-year outlook?

Management said the stronger than expected first half and confidence in the business supported a higher forecast. The new adjusted earnings range is $45.60 to $46.40 a share, up from $44.20 to $45.00.

What are GLP-1 medicines?

GLP-1 medicines are a class of drugs used to treat diabetes and support weight loss. McKesson distributes them to pharmacies, and distribution revenue from these medicines reached $16 billion in the quarter, up 26 percent.

Does this mean McKesson shares are a good buy?

No. This post explains a company earnings report in simple terms. It is educational only, and it does not recommend any investment or financial decision.

Sources

Zacks, “MCK Q2 Earnings Beat Estimates on Specialty Growth, Outlook Raised”, November 5, 2026: https://www.zacks.com/stock/news/3024006/mck-q2-earnings-beat-estimates-on-specialty-growth-outlook-raised

McKesson fiscal second quarter 2027 results, November 4, 2026, as reported by dpa-AFX: https://www.ad-hoc-news.de/boerse/news/corporate-news/mckesson-stock-raises-fiscal-2027-adjusted-eps-guidance/70464163

This article is for general information and education only. It is not legal or financial advice.